Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2024.08.055 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Cathy McShane und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St. James's Hospital, Dublin, Ireland; Wellcome - HRB Clinical Research Facility, St. James's Hospital, James's Stree…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Drug Therapy, Combination, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: A significant proportion of inflammatory bowel disease (IBD) patients fail to respond to advanced therapies. Combining advanced therapies may improve treatment outcome. This study aimed to assess the effectiveness, adverse events, and costs associated with combining advanced therapies in IBD patients. METHODS: Combination advanced therapy was defined as the concurrent use of two biological agents or one biological agent with a small molecule therapy. Clinical data, including disease characteristics, treatment regimens, and adverse events, were collected from electronic patient records. Clinical response rates, biochemical markers, and treatment costs were evaluated. RESULTS: The study included 109 IBD patients receiving combination advanced therapies from 9 academic centers in Ireland. Corticosteroid-free clinical response rates at 12 weeks and 52 weeks were 39 % and 38 %, respectively. Adverse events occurred in 26 % of therapeutic trials, with disease-related events being the most common. Notably, there were 3 cases of non-melanomatous skin cancer and 10 infectious complications. The annual cost of maintenance therapy for combination advanced therapies ranged from €17,560 to €30,724 per patient. CONCLUSION: Combination advanced therapies demonstrated effectiveness and acceptable safety profiles in a cohort of treatment-refractory IBD patients. Further large, prospective trials are required to definitively evaluate the role of combination advanced therapies in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, St. James's Hospital, Dublin, Ireland; Wellcome - HRB Clinical Research Facility, St. James's Hospital, James's Street, Dublin, Ireland; Trinity Academic Gastroenterology Group, Trinity C…
- Mercy University Hospital, Cork, Ireland.
- St Vincent's University Hospital Center for Colorectal Disease, Dublin, Ireland.
- Cork University Hospital, Cork, Ireland.
- Galway University Hospital, Galway, Ireland.
- Beaumont Hospital, Dublin, Ireland.
Zitieren
APA
McShane, C., Varley, R., Fennessy, A., Byron, C., Campion, J. R., Hazel, K., Costigan, C., Ring, E., Marrinan, A., Judge, C., Sugrue, K., Cullen, G., Dunne, C., Hartery, K., Iacucci, M., Kelly, O., Leyden, J., McKiernan, S., O'Toole, A., …, & Kevans, D. (2025). Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.08.055
Vancouver
McShane C, Varley R, Fennessy A, Byron C, Campion JR, Hazel K, et al. Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.08.055
BibTeX
@article{McShane2025,
author = {McShane, Cathy and Varley, Rachel and Fennessy, Anne and Byron, Clodagh and Campion, John Richard and Hazel, Karl and Costigan, Conor and Ring, Eabha and Marrinan, Alan and Judge, Ciaran and Sugrue, Kathleen and Cullen, Garret and Dunne, Cara and Hartery, Karen and Iacucci, Marietta and Kelly, Orlaith and Leyden, Jan and McKiernan, Susan and O'Toole, Aoibhlinn and Sheridan, Juliette and Slattery, Eoin and Boland, Karen and McNamara, Deirdre and Egan, Laurence and Ghosh, Subrata and Doherty, Glen and McCarthy, Jane and Kevans, David},
title = {Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2024.08.055}
}
EUVIMED